Back to search

Article

GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 Diabetes

2026-08-02

Abstract excerpt

<h4>Objective</h4> To identify clinical and genetic factors associated with variation in glycemic response to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with type 2 diabetes, with a focus on common GLP1R variations, polygenic risk load, and pancreas-specific regulation annotation. <h4>Research Design and Methods</h4> We conducted a retrospective cohort study using electronic health r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
08b66ceb-5559-5be3-ac54-564d5ca91adc
DOI
10.64898/2026.07.29.26359248
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesDOI 10.64898/2026.07.29.26359248
Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity
Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity
GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity
Human GLP1R variants affecting GLP1R cell surface expression contribute to impaired glucose control and increased adipositySemantic proximity
Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 DiabetesSemantic proximity
Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity
Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical PracticeSemantic proximity
A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.Semantic proximity
Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Semantic proximity
Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.Semantic proximity
Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.Semantic proximity
Select a neighboring publication to make it the new centre.